BACKGROUND: Experimental findings have suggested that human cytomegalovirus (HCMV) infection of tumor cells may exert oncomodulatory effects that enhance tumor malignancy. However, controversial findings have been published on the presence of HCMV in malignant tumors. Here, we present the first study that systematically investigates HCMV infection in human nervous system tumors by highly sensitive immunohistochemistry in correlation with the HCMV serostatus of the patients. METHODS: Immunohistochemical and quantitative PCR-based methods to detect different HCMV antigens and genomic HCMV DNA were optimized prior to the investigation of pathological samples. Moreover, the pathological results were matched with the HCMV serostatus of the patients. RESULTS: HCMV immediate-early, late, and pp65 antigens could be detected in single cells from HCMV strain Hi91-infected UKF-NB-4 neuroblastoma cells after 1:1024 dilution with noninfected UKF-NB-4 cells. Genomic HCMV DNA could be detected in copy numbers as low as 430 copies/mL. However, we did not detect HCMV in tumors from a cohort of 123 glioblastoma, medulloblastoma, or neuroblastoma patients. Notably, we detected nonspecifically positive staining in tumor tissues of HCMV seropositive and seronegative glioblastoma patients. The HCMV serostatus of 67 glioblastoma patients matched the general epidemiological prevalence data for Western countries (72% of female and 57% of male glioblastoma patients were HCMV seropositive). Median survival was not significantly different in HCMV seropositive versus seronegative glioblastoma patients. CONCLUSIONS: The prevalence of HCMV-infected tumor cells may be much lower than previously reported based on highly sensitive detection methods.
BACKGROUND: Experimental findings have suggested that human cytomegalovirus (HCMV) infection of tumor cells may exert oncomodulatory effects that enhance tumor malignancy. However, controversial findings have been published on the presence of HCMV in malignant tumors. Here, we present the first study that systematically investigates HCMV infection in humannervous system tumors by highly sensitive immunohistochemistry in correlation with the HCMV serostatus of the patients. METHODS: Immunohistochemical and quantitative PCR-based methods to detect different HCMV antigens and genomic HCMV DNA were optimized prior to the investigation of pathological samples. Moreover, the pathological results were matched with the HCMV serostatus of the patients. RESULTS:HCMV immediate-early, late, and pp65 antigens could be detected in single cells from HCMV strainHi91-infected UKF-NB-4 neuroblastoma cells after 1:1024 dilution with noninfected UKF-NB-4 cells. Genomic HCMV DNA could be detected in copy numbers as low as 430 copies/mL. However, we did not detect HCMV in tumors from a cohort of 123 glioblastoma, medulloblastoma, or neuroblastomapatients. Notably, we detected nonspecifically positive staining in tumor tissues of HCMV seropositive and seronegative glioblastomapatients. The HCMV serostatus of 67 glioblastomapatients matched the general epidemiological prevalence data for Western countries (72% of female and 57% of male glioblastomapatients were HCMV seropositive). Median survival was not significantly different in HCMV seropositive versus seronegative glioblastomapatients. CONCLUSIONS: The prevalence of HCMV-infected tumor cells may be much lower than previously reported based on highly sensitive detection methods.
Authors: Kristine Dziurzynski; Susan M Chang; Amy B Heimberger; Robert F Kalejta; Stuart R McGregor Dallas; Martine Smit; Liliana Soroceanu; Charles S Cobbs Journal: Neuro Oncol Date: 2012-02-08 Impact factor: 12.300
Authors: Martin Michaelis; Peter Baumgarten; Michel Mittelbronn; Pablo Hernáiz Driever; Hans Wilhelm Doerr; Jindrich Cinatl Journal: Med Microbiol Immunol Date: 2010-10-22 Impact factor: 3.402
Authors: Sara Sjöström; Ulf Hjalmars; Per Juto; Göran Wadell; Göran Hallmans; Anne Tjönneland; Jytte Halkjaer; Jonas Manjer; Martin Almquist; Beatrice S Melin Journal: Cancer Causes Control Date: 2011-06-30 Impact factor: 2.506
Authors: M Michaelis; S Barth; R Breitling; J Bruch; D Steinberger; F Rothweiler; K Hackmann; E Schröck; H W Doerr; D K Griffin; J Cinatl; J Cinatl Journal: Oncogenesis Date: 2012-04-30 Impact factor: 7.485
Authors: Michael Weller; Patrick Roth; Matthias Preusser; Wolfgang Wick; David A Reardon; Michael Platten; John H Sampson Journal: Nat Rev Neurol Date: 2017-05-12 Impact factor: 42.937
Authors: Nicole A Wilski; Christina Del Casale; Timothy J Purwin; Andrew E Aplin; Christopher M Snyder Journal: J Virol Date: 2019-09-30 Impact factor: 5.103